SG11201810935SA - Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid bearing carboxylate charges and hydrophobic radicals - Google Patents

Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid bearing carboxylate charges and hydrophobic radicals

Info

Publication number
SG11201810935SA
SG11201810935SA SG11201810935SA SG11201810935SA SG11201810935SA SG 11201810935S A SG11201810935S A SG 11201810935SA SG 11201810935S A SG11201810935S A SG 11201810935SA SG 11201810935S A SG11201810935S A SG 11201810935SA SG 11201810935S A SG11201810935S A SG 11201810935SA
Authority
SG
Singapore
Prior art keywords
basal insulin
acid bearing
carboxylate charges
bearing carboxylate
injectable solution
Prior art date
Application number
SG11201810935SA
Inventor
Alexandre Geissler
Ségolène LAAGE
Richard Charvet
Olivier Soula
Original Assignee
Adocia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adocia filed Critical Adocia
Publication of SG11201810935SA publication Critical patent/SG11201810935SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN HAVING A PI OF BETWEEN 5.8 AND 8.5 AND A COPOLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS [0001] The invention relates to physically stable compositions in the form of an injectable aqueous solution, the pH of which is from 6.0 to 8.0, comprising at least: a) a basal insulin of which the isoelectric point (pI) is from 5.8 to 8.5, and b) a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.
SG11201810935SA 2016-06-07 2017-06-07 Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid bearing carboxylate charges and hydrophobic radicals SG11201810935SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1655222A FR3052072A1 (en) 2016-06-07 2016-06-07 PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACIDE CARRYING CARBOXYLATE LOADS AND HYDROPHOBIC RADICALS
PCT/EP2017/063865 WO2017211903A1 (en) 2016-06-07 2017-06-07 Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid bearing carboxylate charges and hydrophobic radicals

Publications (1)

Publication Number Publication Date
SG11201810935SA true SG11201810935SA (en) 2019-01-30

Family

ID=57348773

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201810937WA SG11201810937WA (en) 2016-06-07 2017-06-07 Injectable solution at ph 7, comprising at least one basal insulin whose pi is between 5.8 and 8.5, a prandial insulin and/or a gastrointestinal hormone, and a copolyamino acid bearing carboxylate charges and hydrophobic radicals
SG11201810935SA SG11201810935SA (en) 2016-06-07 2017-06-07 Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid bearing carboxylate charges and hydrophobic radicals

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201810937WA SG11201810937WA (en) 2016-06-07 2017-06-07 Injectable solution at ph 7, comprising at least one basal insulin whose pi is between 5.8 and 8.5, a prandial insulin and/or a gastrointestinal hormone, and a copolyamino acid bearing carboxylate charges and hydrophobic radicals

Country Status (12)

Country Link
US (2) US10548952B2 (en)
EP (2) EP3463293B1 (en)
JP (1) JP2019517555A (en)
CN (2) CN109640953B (en)
BR (2) BR112018075140A2 (en)
EA (2) EA039363B1 (en)
FR (1) FR3052072A1 (en)
MX (2) MX2018015068A (en)
PH (1) PH12018502558A1 (en)
SA (2) SA518400588B1 (en)
SG (2) SG11201810937WA (en)
WO (2) WO2017211916A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3070264A1 (en) * 2017-08-24 2019-03-01 Adocia PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN INCLUDING AN INHIBIT OF 5.8 TO 8.5 AND A CO-POLYAMINOACIDE CARBOXYLATE AND HYDROPHOBIC RADICAL CARRIERS
FR3083089A1 (en) * 2018-06-29 2020-01-03 Adocia PH 7 INJECTION SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACID CARRYING CARBOXYLATES AND HYDROPHOBIC RADICALS
MX2020005913A (en) 2017-12-07 2020-10-19 Adocia Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals.
FR3083086A1 (en) * 2018-06-29 2020-01-03 Adocia COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID
US20190275108A1 (en) * 2017-12-07 2019-09-12 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analogue and a co-polyamino acid
KR20200106892A (en) 2017-12-07 2020-09-15 아도시아 A solution for injection at pH 7 comprising at least one basal insulin with a pI of 5.8 to 8.5, and a co-polyamino acid bearing a carboxylate charge and a hydrophobic radical
US20190216931A1 (en) 2017-12-07 2019-07-18 Adocia Injectable ph 7 solution comprising at least one basal insulin having a pi from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP3740195A1 (en) * 2017-12-07 2020-11-25 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
BR112020011479A2 (en) 2017-12-07 2020-11-17 Adocia compositions in the form of an aqueous solution for injection characterized by the fact that it comprises amylin, an amylin receptor agonist or an amylin analog and a co-polyamino acid
FR3067247A1 (en) * 2018-06-07 2018-12-14 Adocia COMPOSITIONS IN THE FORM OF AN INJECTION AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINOACID
WO2019243628A1 (en) * 2018-06-22 2019-12-26 Adocia Injectable composition with a ph of 7 comprising a co-polyaminoacid bearing carboxylate charges and hydrophobic radicals and at least one basal insulin having at least a prandial effect and a basal effect
FR3084585B1 (en) * 2018-08-03 2020-11-06 Adocia SOLUTION FOR INJECTION AT PH 7 INCLUDING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 AND AN AMPHIPHILIC COMPOUND CARRIER OF HYDROPHOBIC RADICALS
FR3084586B1 (en) * 2018-08-03 2020-11-06 Adocia COMPOSITIONS IN THE FORM OF AN AQUEOUS SOLUTION FOR INJECTION CONSISTING OF AMYLINE, AN AMYLINE RECEPTOR AGONIST OR ANALOGUE OF AMYLINE AND AN AMPHIPHILIC COMPOUND CARRIER OF HYDROPHOBIC RADICALS
WO2020115334A1 (en) * 2018-12-07 2020-06-11 Adocia Method for preparing a stable composition in the form of an injectable aqueous solution
US20200179489A1 (en) * 2018-12-07 2020-06-11 Adocia Injectable solution at ph 7 comprising at least one basal insulin which pi is from 5.8 to 8.5 and a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals and a limited amount of m-cresol
WO2020245470A1 (en) 2019-06-07 2020-12-10 Adocia Injectable solution at ph 7 containing at least one basal insulin, the pi of which is between 5.8 and 8.5, liraglutide, and a copolyamino acid carrying carboxylate charges and hydrophobic radicals

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826818A (en) 1983-10-26 1989-05-02 Kanebo Ltd. Proteinaceous emulsifier, process for preparing same and emulsion type cosmetic compositions containing same
DE3837825A1 (en) 1988-11-08 1990-05-10 Hoechst Ag NEW INSULIN DERIVATIVES, THEIR USE AND A PHARMACEUTICAL PREPARATION CONTAINING THEM
FR2801226B1 (en) 1999-11-23 2002-01-25 Flamel Tech Sa COLLOIDAL SUSPENSION OF SUBMICRONIC PARTICLES FOR VECTORIZATION OF ACTIVE INGREDIENTS AND METHOD OF PREPARATION
IL161848A0 (en) 2001-12-20 2005-11-20 Lilly Co Eli Insulin moldecule having protracted time action
FR2840614B1 (en) 2002-06-07 2004-08-27 Flamel Tech Sa POLYAMINOACIDS FUNCTIONALIZED BY ALPHA-TOCOPHEROL AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
WO2004096854A2 (en) 2003-04-29 2004-11-11 Eli Lilly And Company Insulin analogs having protracted time action
FR2862535B1 (en) * 2003-11-21 2007-11-23 Flamel Tech Sa PHARMACEUTICAL FORMULATIONS FOR PROLONGED RELEASE OF INTERLEUKINS AND THEIR THERAPEUTIC APPLICATIONS
FR2915683B1 (en) * 2007-05-03 2009-08-07 Flamel Technologies Sa SELF-PRECIPITANT PHARMACEUTICAL FORMULATIONS FOR MODIFIED RELEASE OF ACTIVE INGREDIENTS
US9089476B2 (en) * 2011-08-10 2015-07-28 Adocia Injectable solution at pH 7 comprising at least one basal insulin whose PI is between 5.8 and 8.5
FR2985429B1 (en) 2012-01-09 2016-07-29 Adocia PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A SUBSTITUTED POLYAMINOACID OBTAINED BY A CONTROLLED POLYMERIZATION PROCESS
EP2814461B1 (en) * 2012-01-09 2019-07-24 Adocia Injectable solution having a ph of 7 and including at least basal insulin, the pi of which is between 5.8 and 8.5, and a substituted co-poly(amino acid)
FR3001896B1 (en) 2013-02-12 2015-07-03 Adocia PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WHERE THE ISO-ELECTRIC POINT IS BETWEEN 5.8 AND 8.5 AND A HYDROPHOBIC ANIONIC POLYMER
FR3001895B1 (en) 2013-02-12 2015-07-03 Adocia PH7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WHERE THE ISOELECTRIC POINT IS INCLUDED IN 5.8 AND 8.5 AND AN ANIONIC COMPOUND CARRYING CARBOXYLATE LOADS AND HYDROPHOBIC RADICALS

Also Published As

Publication number Publication date
EP3463292A1 (en) 2019-04-10
SA518400596B1 (en) 2022-03-16
EP3463293B1 (en) 2021-05-12
WO2017211903A1 (en) 2017-12-14
JP2019517555A (en) 2019-06-24
US20170348396A1 (en) 2017-12-07
CN109640953B (en) 2021-10-29
FR3052072A1 (en) 2017-12-08
CN109640953A (en) 2019-04-16
PH12018502558A1 (en) 2019-10-14
US10383920B2 (en) 2019-08-20
CN109379888B (en) 2021-10-29
MX2018015067A (en) 2019-05-09
EP3463293A1 (en) 2019-04-10
EA201892737A1 (en) 2019-05-31
BR112018075140A2 (en) 2019-03-26
WO2017211916A1 (en) 2017-12-14
CN109379888A (en) 2019-02-22
US10548952B2 (en) 2020-02-04
MX2018015068A (en) 2019-05-09
EP3463292B1 (en) 2020-08-05
EA039363B1 (en) 2022-01-18
EA039333B1 (en) 2022-01-14
SA518400588B1 (en) 2022-03-07
SG11201810937WA (en) 2019-01-30
US20170348423A1 (en) 2017-12-07
EA201892736A1 (en) 2019-05-31
BR112018075151A2 (en) 2019-03-26

Similar Documents

Publication Publication Date Title
SA518400588B1 (en) Injectable Solution at PH 7 Comprising at Least One Basal Insulin The PI of Which is From 5.8 to 8.5 and A Co-Polyamino Acid Bearing Carboxylate Charges and Hydrophobic Radicals
PH12020550827A1 (en) Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
SG11201810939PA (en) Compositions in the form of an injectable aqueous solution, comprising human glucagon and an end-grafted copolyamino acid
WO2019110797A8 (en) Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
PH12020550828A1 (en) Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
BR112018010805A2 (en) rsv f protein mutants
MX2014001190A (en) Injectable solution of at least one type of basal insulin.
PH12020550804A1 (en) Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
IL275148A (en) Injectable solution with a ph of 7 comprising at least one basal insulin with a pi of between 5.8 and 8.5 and a co-polyaminoacid bearing carboxylate charges and hydrophobic radicals
SG11202005322RA (en) Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
NZ730790A (en) Composition of (6s)-5-methyl tetrahydrofolic acid or salt thereof as well as preparation therefor and application thereof
SG11202000625PA (en) Compositions in the form of an injectable aqueous solution comprising at least human insulin a21g and a prandial action glucagon suppressor
MX2015015162A (en) Uric acid level lowering agent.
IN2014CN02188A (en)
EA201890075A1 (en) INJECTABLE PHARMACEUTICAL COMPOSITIONS LEFAMULIN
MX363604B (en) Composition comprising a combination of an acrylic polymer, a silicone copolymer and an amino acid or amino acid derivative.
MX2016004328A (en) Immunopotentiator.
MX2021006187A (en) Stable aqueous composition comprising oligosaccharides.
MY193928A (en) Aqueous primer
EA202091374A1 (en) SOLUTION FOR INJECTION WITH pH 7, CONTAINING AT LEAST ONE BASAL INSULIN WITH pI BETWEEN 5.8 AND 8.5 AND COPOLYAMINO ACID CARBOXYLATE CARRIED OUT AND HYDROPHOBIC RADICALS
ZA202109597B (en) Method for stabilizing the ph of an aqueous composition comprising a drug
MX2020006670A (en) Aqueous composition comprising 2-(dimethyl-1h-pyrazole-1-yl) succinic acid and ammonia.
MX2016010431A (en) Compositions for preventing and/or treating pathological conditions associated with alpha-glucosidase.
FR3074681B1 (en) PH 7 INJECTION SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACID CARRYING CARBOXYLATES AND HYDROPHOBIC RADICALS
SG11201804902UA (en) A composition for improving memory, learning ability, and cognitive ability